The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...

Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast ...

She emphasized that while elacestrant has properties similar to other agents, imlunestrant is closer to a “pure” ER ...

BUFFALO, NY – August 13, 2025 – A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase ...

Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by postmenopausal women with early-stage breast cancer. Changes in cognitive function in postmenopausal women 1 year after completing ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Outcomes of children exposed to chemotherapy in utero for breast cancer. Background: PTC299, an oral investigational drug, suppresses tumor growth by selective posttranscriptional inhibition of tumor ...